OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury
Recruiting now
Conditions studied: Myocardial Ischemia-Reperfusion Injury
In brief
This study examines how the interaction between octanal (an OR6A2 receptor activator) and OR6A2 expression influences inflammation and clinical outcomes in Myocardial Ischemia-Reperfusion Injury patients. We analyze two key relationships: 1) The octanal-OR6A2 pathway's association with systemic oxidative stress/inflammatory biomarkers, and 2) How OR6A2 expression patterns on monocyte subtypes and plasma octanal levels correlate with major cardiovascular events. Patients undergoing this post-revascularization injury provided blood samples for OR6A2/octanal/inflammation measurements. IR Injury patients underwent 44-month clinical follow-up. Results may identify biological markers for personalized risk assessment after revascularization therapies. Ethics approval: Zhongda Hospital #2020ZDSYLL051-P01.
Key facts
- Study ID
- NCT07100457
- Run by
- Southeast University, China
- People needed
- 200
- Starts
- 2019-09-01
- Expected to finish
- 2027-08-30
- Last updated by the study team
- 2025-08-03
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Acute myocardial infarction (AMI) patients with angiographically-confirmed coronary artery disease undergoing primary percutaneous coronary intervention (PCI), and subsequently diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period.
- Age 18-90 years inclusive.
You may not qualify if…
- Active systemic infections.
- Advanced heart failure (NYHA class III-IV).
- Acute cerebrovascular conditions.
- Active myocarditis.
- cardiomyopathy.
- Refractory ventricular tachycardia/fibrillation.
- Diagnosis/concurrent treatment for malignancy within 5 years (except non-melanoma skin cancer/carcinoma in situ).
- Severe renal insufficiency (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73m2 or dialysis dependence).
- Child-Pugh class C hepatic dysfunction.
Where it is running
- Department of Cardiology, Zhongda Hospital, Southeast University — Nanjing, Jiangsu, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.